Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 23Carboplatin 23Paclitaxel 17Specimen Handling 15Magnetic Resonance Spectroscopy 11Cyclophosphamide 10Biopsy 10Taxes 7Capecitabine 7Nivolumab 6130-nm albumin-bound paclitaxel 6sacituzumab govitecan 5Gemcitabine 5Doxorubicin 5Albumin-Bound Paclitaxel 5Fulvestrant 4olaparib 3fludarabine 3eribulin 3durvalumab 3atezolizumab 3Letrozole 3Epirubicin 3Bevacizumab 3veliparib 2poly ICLC 2pertuzumab 2aldesleukin 2abemaciclib 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × 18-O-demethylcervinomycin A2 × 30 days × Clear all
NCT05445908 2026-05-08

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Active not recruiting
175 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡